Dabigatran: Uses, Dosage & Side Effects
Direct oral anticoagulant (NOAC) – direct thrombin inhibitor for stroke prevention and blood clot treatment
Quick facts about Dabigatran
Key Takeaways
- Dabigatran is a direct oral anticoagulant (NOAC) that prevents blood clots by directly and reversibly inhibiting thrombin (factor IIa), the central enzyme in the coagulation cascade.
- The RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in atrial fibrillation, while the 110 mg dose showed non-inferior efficacy with significantly less major bleeding.
- Dabigatran is the only NOAC with a specific approved reversal agent – idarucizumab (Praxbind) – which completely reverses its anticoagulant effect within minutes in emergency situations.
- Renal function monitoring is essential, as approximately 80% of dabigatran is eliminated unchanged by the kidneys. It is contraindicated in severe renal impairment (CrCl <30 mL/min in most countries).
- Capsules must be swallowed whole – they must never be opened, crushed, or chewed, as this can increase bioavailability by up to 75% and dramatically raise bleeding risk.
What Is Dabigatran and What Is It Used For?
Quick Answer: Dabigatran etexilate is a direct oral anticoagulant (NOAC) that belongs to the class of direct thrombin inhibitors. It is used to prevent stroke in atrial fibrillation, treat and prevent deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery. It is also approved for the treatment of venous thromboembolism in children.
Dabigatran etexilate is a prescription anticoagulant medication that works through a unique mechanism among the direct oral anticoagulants. Unlike the factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), dabigatran directly and reversibly inhibits thrombin (factor IIa), the final serine protease in the coagulation cascade. Thrombin plays a central role in haemostasis: it converts fibrinogen to fibrin, activates factors V, VIII, XI, and XIII, and stimulates platelet aggregation. By directly blocking thrombin, dabigatran prevents all of these downstream effects, effectively inhibiting blood clot formation.
Dabigatran etexilate is a prodrug – it has minimal pharmacological activity itself and must be converted to its active form, dabigatran, through rapid esterase-catalysed hydrolysis in the plasma and liver. This conversion occurs independently of cytochrome P450 enzymes, which gives dabigatran a distinct pharmacological profile with fewer metabolic drug interactions compared to many other medications.
Originally developed by Boehringer Ingelheim and marketed under the brand name Pradaxa, dabigatran was the first direct oral anticoagulant to receive regulatory approval, gaining European Medicines Agency (EMA) approval in 2008 and U.S. Food and Drug Administration (FDA) approval in 2010. Since then, multiple generic versions have become available, including Dabigatran Etexilate Accord, Dabigatran etexilate Medical Valley, Dabigatran etexilate Glenmark, and Dabigatran etexilate Krka.
Dabigatran belongs to the broader class of direct oral anticoagulants (DOACs), also referred to as novel oral anticoagulants (NOACs). This group has largely replaced warfarin as the first-line oral anticoagulant for many conditions due to predictable pharmacology, fixed dosing, and the absence of routine blood monitoring requirements. Among the DOACs, dabigatran holds a unique position as the only one that directly inhibits thrombin rather than factor Xa, and the only one with a specific, approved reversal agent (idarucizumab).
Approved Indications
Dabigatran etexilate is approved for the following clinical indications across major regulatory agencies (EMA, FDA, and other national authorities):
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, hypertension, diabetes mellitus, or symptomatic heart failure (NYHA class ≥II).
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, following initial parenteral anticoagulation for at least 5 days.
- Prevention of recurrent DVT and PE in adults who have completed initial treatment.
- Prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery (primary prevention).
- Treatment and prevention of venous thromboembolism (VTE) in children from birth onwards (EMA-approved indication), using weight-based and age-based dosing with coated granule formulation or capsules for older children.
The European Society of Cardiology (ESC) 2024 guidelines recommend DOACs, including dabigatran, as the preferred oral anticoagulants over warfarin for stroke prevention in patients with atrial fibrillation, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis. The American Heart Association/American College of Cardiology (AHA/ACC) guidelines similarly recommend DOACs as first-line therapy in eligible patients.
Mechanism of Action
Dabigatran is a potent, competitive, reversible direct thrombin inhibitor. After oral administration, the prodrug dabigatran etexilate is rapidly converted to dabigatran by esterase-mediated hydrolysis. Dabigatran binds to the active site of thrombin with high specificity, inhibiting both free thrombin and fibrin-bound thrombin, as well as thrombin-induced platelet aggregation. This comprehensive thrombin inhibition distinguishes dabigatran from indirect thrombin inhibitors (such as heparin), which can only inhibit free thrombin.
By blocking thrombin, dabigatran prevents the conversion of fibrinogen to fibrin, the activation of coagulation factors V, VIII, XI, and XIII, and the thrombin-mediated stimulation of platelet activation. This effectively disrupts the final common pathway of the coagulation cascade. The reversible binding to thrombin means that the anticoagulant effect diminishes as dabigatran is cleared from the body, primarily through renal excretion.
What Should You Know Before Taking Dabigatran?
Quick Answer: Before starting dabigatran, your doctor must assess your kidney function (creatinine clearance), bleeding risk, and current medications. Dabigatran is contraindicated in severe renal impairment, active bleeding, prosthetic heart valves, and concurrent use of certain drugs including systemic ketoconazole, ciclosporin, and dronedarone. Kidney function must be monitored regularly throughout treatment.
Before prescribing dabigatran, your healthcare provider will conduct a thorough assessment of your medical history, current medications, kidney and liver function, and overall health status. Because dabigatran is predominantly eliminated by the kidneys (approximately 80% excreted unchanged in urine), renal function assessment is particularly critical and sets dabigatran apart from the factor Xa inhibitors in terms of pre-treatment evaluation requirements.
Contraindications
Dabigatran should not be used in the following situations:
- Hypersensitivity: Known allergy to dabigatran etexilate or any of the excipients in the formulation.
- Severe renal impairment: Creatinine clearance (CrCl) below 30 mL/min. Dabigatran is predominantly renally cleared, and severe renal impairment leads to dangerously elevated drug levels and increased bleeding risk.
- Active clinically significant bleeding: Patients with ongoing haemorrhage from any site.
- Lesions at risk of significant bleeding: Such as current or recent gastrointestinal ulceration, brain or spinal injury, recent brain, spinal, or ophthalmic surgery, malignant neoplasms at high bleeding risk, or oesophageal varices.
- Increased bleeding tendency: Whether congenital, of unknown cause, or due to other medications.
- Concurrent anticoagulant therapy: Use with other anticoagulants (warfarin, rivaroxaban, apixaban, heparin) is contraindicated, except during transitioning between treatments or when heparin is used to maintain catheter patency.
- Severe hepatic impairment: Liver disease that could be life-threatening or is associated with coagulopathy.
- Concurrent use of systemic ketoconazole or itraconazole: Strong P-glycoprotein (P-gp) inhibitors that dramatically increase dabigatran levels.
- Concurrent use of ciclosporin: A potent P-gp inhibitor.
- Concurrent use of dronedarone: Increases dabigatran exposure to unacceptable levels.
- Concurrent use of glecaprevir/pibrentasvir: Antiviral combination for hepatitis C that significantly increases dabigatran levels.
- Prosthetic heart valves: Requiring permanent anticoagulation. The RE-ALIGN trial demonstrated unacceptable rates of thromboembolic and bleeding events in patients with mechanical heart valves treated with dabigatran, leading to this absolute contraindication.
Premature discontinuation of dabigatran without switching to an alternative anticoagulant increases the risk of thrombotic events, including stroke. If you need to stop dabigatran for surgery or other reasons, your doctor will provide specific guidance on when to stop and restart the medication. Never stop taking dabigatran without consulting your prescriber.
Warnings and Precautions
Special caution is required when using dabigatran in the following situations:
- Renal impairment: Because approximately 80% of dabigatran is excreted unchanged by the kidneys, renal function must be assessed before initiation and monitored regularly. For patients aged under 75 with no renal impairment, reassessment should occur at least annually. For patients aged ≥75, or with renal impairment, or in clinical situations suggesting declining renal function (e.g. dehydration, use of nephrotoxic drugs), more frequent monitoring (every 3–6 months) is recommended. In moderate renal impairment (CrCl 30–50 mL/min), dose reduction is required for some indications.
- Increased bleeding risk: Conditions including recent biopsy or major trauma, active peptic ulcer disease, gastric or oesophageal inflammation, gastro-oesophageal reflux, bacterial endocarditis, and thrombocytopenia. Concomitant use of antiplatelet agents or NSAIDs further increases bleeding risk.
- Surgical procedures: Dabigatran must be temporarily discontinued before surgery due to increased bleeding risk. The timing of discontinuation depends on renal function and the bleeding risk of the procedure. For standard-risk procedures, dabigatran should typically be stopped 24 hours before surgery (48 hours if CrCl 30–50 mL/min). For high-risk procedures, longer cessation periods are required.
- Spinal or epidural anaesthesia: Patients receiving neuraxial anaesthesia or undergoing spinal/epidural puncture are at risk of developing epidural or spinal haematoma, which may result in long-term or permanent paralysis. Strict timing guidelines for discontinuation and reinitiation must be followed.
- Hepatic impairment: Patients with liver disease associated with changes in coagulation tests should not use dabigatran. Although dabigatran does not undergo significant hepatic metabolism, elevated liver enzymes (>2× ULN) were an exclusion criterion in clinical trials.
- Antiphospholipid syndrome: Use of DOACs including dabigatran is not recommended in patients with antiphospholipid syndrome, particularly triple-positive patients, due to increased risk of recurrent thrombotic events compared with warfarin.
- Myocardial infarction risk: A numerical increase in myocardial infarction events was observed with dabigatran compared with warfarin in the RE-LY trial, although this did not reach statistical significance. Patients with coronary artery disease risk factors should be monitored.
Pregnancy and Breastfeeding
There are limited data on the use of dabigatran during pregnancy. Animal studies have shown adverse effects on reproductive development. As a precautionary measure, dabigatran is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. Women of childbearing potential should discuss contraception with their doctor while taking dabigatran.
There are no clinical data on the effect of dabigatran on the breastfed infant. Animal studies have shown that dabigatran is excreted in breast milk. Breastfeeding should be discontinued during treatment with dabigatran. A decision must be made whether to discontinue breastfeeding or to discontinue dabigatran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Creatinine clearance (CrCl) must be calculated before starting dabigatran. During treatment, reassess renal function: annually in all patients; every 6 months in patients aged ≥75 or with known renal impairment; and whenever clinical events suggest a potential change (dehydration, intercurrent illness, new nephrotoxic medications). A simple formula: frequency of monitoring in months = CrCl / 10 (e.g. CrCl 40 mL/min → recheck every 4 months).
How Does Dabigatran Interact with Other Drugs?
Quick Answer: Dabigatran is a substrate for P-glycoprotein (P-gp) but is not significantly metabolised by cytochrome P450 enzymes. Strong P-gp inhibitors (ketoconazole, itraconazole, ciclosporin, dronedarone) are contraindicated. P-gp inducers (rifampicin, St John’s Wort) significantly reduce dabigatran levels. Concomitant use of other anticoagulants, antiplatelet agents, and NSAIDs increases bleeding risk.
The drug interaction profile of dabigatran is distinctly different from other oral anticoagulants. Unlike warfarin (which interacts with numerous CYP enzymes and vitamin K) and the factor Xa inhibitors (which are CYP3A4 substrates), dabigatran is not metabolised by cytochrome P450 enzymes. Instead, its primary interaction pathway is through P-glycoprotein (P-gp), the drug efflux transporter. This means that drugs which inhibit or induce P-gp can significantly alter dabigatran plasma levels.
The prodrug dabigatran etexilate (but not the active metabolite dabigatran) is a P-gp substrate. P-gp is expressed in the intestinal epithelium, where it limits drug absorption. Inhibitors of P-gp increase dabigatran absorption and plasma levels, while inducers reduce them. Understanding these interactions is critical for safe prescribing.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Ketoconazole, itraconazole (systemic) | Strong P-gp inhibitors; dramatically increase dabigatran levels (140–150% increase) | Contraindicated – do not co-administer |
| Ciclosporin | Potent P-gp inhibitor; expected to substantially increase dabigatran levels | Contraindicated – do not co-administer |
| Dronedarone | P-gp inhibitor; increases dabigatran AUC by approximately 70–100% | Contraindicated – do not co-administer |
| Glecaprevir/pibrentasvir | P-gp inhibitors; significantly increase dabigatran levels | Contraindicated – do not co-administer |
| Rifampicin | Strong P-gp inducer; decreases dabigatran levels by approximately 66% | Avoid concomitant use; dabigatran efficacy is substantially reduced |
| Phenytoin, carbamazepine, phenobarbital | P-gp inducers; expected to significantly decrease dabigatran levels | Avoid concomitant use |
| St John’s Wort (Hypericum perforatum) | P-gp inducer; expected to decrease dabigatran levels | Avoid concomitant use |
| Other anticoagulants (warfarin, heparin, rivaroxaban, apixaban) | Additive anticoagulant effect; markedly increased bleeding risk | Contraindicated except during transition between agents |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Amiodarone | P-gp inhibitor; increases dabigatran AUC by approximately 50–60% | Consider dose reduction to 150 mg twice daily (AF indication); no adjustment needed for VTE prevention post-surgery |
| Verapamil | P-gp inhibitor; increases dabigatran levels by 12–180% depending on timing and formulation | Reduce dose; take dabigatran at least 2 hours before verapamil. Avoid with extended-release verapamil in some indications |
| Quinidine | P-gp inhibitor; increases dabigatran levels by approximately 50% | Consider dose reduction; use with caution |
| Tacrolimus | P-gp inhibitor; expected to increase dabigatran levels | Use with caution; monitor for signs of bleeding |
| Clarithromycin | P-gp inhibitor; may increase dabigatran levels | Use with caution; monitor for signs of bleeding |
| NSAIDs (ibuprofen, diclofenac, naproxen) | Do not alter dabigatran levels but independently increase bleeding risk, particularly gastrointestinal | Use with caution; avoid long-term concomitant use if possible |
| Aspirin, clopidogrel, prasugrel, ticagrelor | Antiplatelet agents; additive bleeding risk | Use only when clinically indicated; shortest duration possible |
| SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine) | May impair platelet function and increase bleeding risk | Use with caution; monitor for unusual bleeding |
Unlike warfarin, dabigatran does not interact with vitamin K-containing foods. You do not need to restrict your diet. However, dabigatran capsules must not be mixed with milk or foods containing dairy products (this applies to the coated granule paediatric formulation). Proton pump inhibitors (e.g. omeprazole, pantoprazole) may reduce dabigatran absorption by approximately 20–30%, but no dose adjustment is recommended as this reduction is not considered clinically significant.
What Is the Correct Dosage of Dabigatran?
Quick Answer: The standard dose of dabigatran for stroke prevention in atrial fibrillation is 150 mg twice daily, with a reduced dose of 110 mg twice daily for patients aged ≥80, those taking verapamil, or those at high bleeding risk. For VTE prevention after surgery, the dose is 220 mg once daily (or 150 mg once daily for elderly or moderate renal impairment). Capsules must be taken approximately 12 hours apart for twice-daily regimens.
Dabigatran dosing varies by indication, age, renal function, and concomitant medications. Unlike warfarin, dabigatran uses fixed doses without the need for routine INR monitoring. However, selecting the correct dose is essential, as both underdosing (increased thrombotic risk) and overdosing (increased bleeding risk) can have serious consequences. Always take the exact dose prescribed by your doctor.
Adults – Atrial Fibrillation
| Patient Group | Dose | Duration |
|---|---|---|
| Standard dose (adults <80 years) | 150 mg twice daily | Long-term (indefinite) |
| Patients aged ≥80 years | 110 mg twice daily | Long-term (indefinite) |
| Patients taking verapamil | 110 mg twice daily (EMA); dose adjustment varies by region | Long-term (indefinite) |
| Moderate renal impairment (CrCl 30–50 mL/min) | 150 mg or 110 mg twice daily (based on individual risk assessment) | Long-term with regular renal monitoring |
| High bleeding risk (gastritis, oesophagitis, GI reflux) | 110 mg twice daily may be considered | Long-term; reassess risk periodically |
Adults – Treatment of DVT and PE
For the treatment of deep vein thrombosis and pulmonary embolism, dabigatran is used following an initial course of parenteral anticoagulation (e.g. heparin or low-molecular-weight heparin) for at least 5 days. The recommended dose is 150 mg twice daily. For patients aged ≥80 years or those taking verapamil, the dose of 110 mg twice daily should be considered. Treatment duration depends on the individual clinical situation, typically at least 3 months and potentially long-term for recurrent VTE or ongoing risk factors.
Adults – VTE Prevention After Surgery
| Surgery Type | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Elective hip replacement | 220 mg once daily (110 mg first dose, 1–4 hours post-surgery) | 150 mg once daily (75 mg first dose)* | 28–35 days |
| Elective knee replacement | 220 mg once daily (110 mg first dose, 1–4 hours post-surgery) | 150 mg once daily (75 mg first dose)* | 10 days |
*Reduced dose criteria: 150 mg once daily for patients aged ≥75, those with moderate renal impairment (CrCl 30–50 mL/min), or those taking concomitant verapamil, amiodarone, or quinidine.
Children
Dabigatran is approved for the treatment and prevention of venous thromboembolism in children from birth to under 18 years of age. Dosing is based on body weight and age, using specific weight–age combination tables to determine the appropriate dose. For children under 12 years, a coated granule formulation is available, mixed with apple juice or soft food (not dairy products). Children aged 8 and older may use capsules if able to swallow them whole. Dosing is given twice daily, approximately 12 hours apart. The prescribing physician will determine the exact dose based on the child’s weight and age using the detailed dosing tables provided in the prescribing information.
Missed Dose
If you miss a dose of dabigatran, take it as soon as you remember, provided there are still 6 or more hours remaining until the next scheduled dose. If fewer than 6 hours remain before the next dose, skip the missed dose entirely and take the next dose at the usual time. Never take a double dose to compensate for a missed one. Missing doses increases the risk of blood clots, so it is important to take dabigatran as consistently as possible.
Overdose
In case of overdose, seek immediate medical attention. Dabigatran has a specific reversal agent – idarucizumab (Praxbind) – which can be administered intravenously to completely and immediately reverse the anticoagulant effect. This is a significant advantage of dabigatran over factor Xa inhibitors in overdose situations. Additionally, dabigatran can be removed by haemodialysis (approximately 60% cleared over 2–3 hours) due to its low plasma protein binding (approximately 35%), which is not possible with the highly protein-bound factor Xa inhibitors. Activated charcoal may reduce absorption if given within 2 hours of ingestion.
If you suspect an overdose of dabigatran, contact your local poison control centre or go to the nearest emergency department immediately. Symptoms of overdose may include unusual bleeding, blood in urine or stool, excessive bruising, or prolonged bleeding from cuts. Do not attempt to induce vomiting unless instructed by a healthcare professional. Inform medical staff that you are taking dabigatran, as the specific reversal agent idarucizumab may be needed.
Dabigatran capsules must be swallowed whole with a glass of water. They must never be opened, crushed, or chewed. Breaking the capsule increases the bioavailability of the drug by up to 75%, which dramatically increases the risk of serious or life-threatening bleeding. If you have difficulty swallowing capsules, discuss alternative formulations or medications with your doctor.
What Are the Side Effects of Dabigatran?
Quick Answer: The most common side effects of dabigatran are bleeding-related events and gastrointestinal symptoms (dyspepsia, gastro-oesophageal reflux, nausea). In the RE-LY trial, dabigatran 110 mg twice daily had significantly lower rates of major bleeding than warfarin, while the 150 mg dose had similar major bleeding rates but lower intracranial haemorrhage. Gastrointestinal bleeding may be slightly higher with dabigatran 150 mg compared to warfarin.
As with all anticoagulant medications, the most significant risk associated with dabigatran is bleeding. The landmark RE-LY trial, which compared two doses of dabigatran (110 mg and 150 mg twice daily) with warfarin in over 18,000 patients with atrial fibrillation, provided extensive safety data. Dabigatran 150 mg twice daily had similar rates of major bleeding to warfarin (3.11% vs 3.36% per year), while dabigatran 110 mg had significantly lower rates (2.71% per year, p = 0.003). Both doses had significantly lower rates of intracranial haemorrhage compared with warfarin (0.23% and 0.30% vs 0.74% per year).
A distinctive side effect profile of dabigatran, compared with other DOACs, is the higher incidence of gastrointestinal symptoms, particularly dyspepsia. This is thought to be related to the tartaric acid core of the capsule formulation, which creates a low-pH microenvironment to enhance drug absorption. Taking dabigatran with food or a glass of water may help reduce these symptoms.
Common
Affects 1–10 in 100 patients
- Decreased red blood cell count (anaemia)
- Decreased platelet count (thrombocytopenia)
- Skin rash with dark red, raised, itchy bumps (allergic reaction)
- Sudden change in skin colour and appearance
- Bruising (haematoma, ecchymosis)
- Nosebleeds (epistaxis)
- Gastro-oesophageal reflux / acid reflux
- Nausea
- Vomiting
- Diarrhoea or loose stools
- Dyspepsia (indigestion, stomach discomfort)
- Hair loss (alopecia)
- Elevated liver enzymes
Uncommon
Affects 1–10 in 1,000 patients
- Decreased white blood cell count (leucopenia)
- Gastrointestinal bleeding (stomach, intestinal)
- Intracranial bleeding (bleeding in the brain)
- Rectal bleeding
- Urogenital bleeding (blood in urine, vaginal or penile bleeding)
- Bleeding under the skin
- Decreased haemoglobin
- Lower proportion of blood cells (haematocrit decrease)
- Pruritus (itching)
- Haemoptysis (coughing up blood or blood-stained sputum)
- Abdominal pain / stomach pain
- Oesophagitis / gastritis (inflammation of oesophagus or stomach)
- Allergic reactions
- Difficulty swallowing (dysphagia)
- Jaundice (yellowing of skin or eyes due to liver or blood problems)
Rare / Frequency Not Known
Affects fewer than 1 in 1,000 patients or unknown frequency
- Agranulocytosis (severe lack of white blood cells)
- Severe allergic reactions causing breathing difficulty or dizziness (anaphylaxis)
- Severe allergic reactions causing swelling of face or throat (angioedema)
- Wheezing or difficulty breathing (bronchospasm)
- Joint bleeding (haemarthrosis)
- Bleeding from a wound, surgical site, or injection site
- Haemorrhoidal bleeding
- Gastric or duodenal ulcer (including oesophageal ulcer)
- Abnormal liver function tests
- Severe or uncontrollable bleeding from any site
- Blood in vomit or vomit that looks like coffee grounds
- Black or tarry stools, or bright red blood in stool
- Pink or brown urine
- Sudden severe headache, confusion, vision changes, or weakness on one side (signs of intracranial bleeding)
- Numbness or weakness in the legs, or problems with bowel or bladder function after spinal/epidural anaesthesia
- Signs of allergic reaction: swelling of face, lips, tongue or throat, difficulty breathing, severe skin rash
Post-marketing surveillance has confirmed the safety profile observed in clinical trials. A large real-world study by the FDA (the Mini-Sentinel analysis) involving over 134,000 Medicare patients found that dabigatran was associated with a lower risk of intracranial haemorrhage, ischaemic stroke, and death compared with warfarin in the general population of elderly patients with atrial fibrillation, consistent with the RE-LY findings.
How Should You Store Dabigatran?
Quick Answer: Store dabigatran capsules in the original packaging to protect from moisture. Do not transfer capsules to pill organisers or other containers. Keep out of reach of children. Once the blister or bottle is opened, capsules must be used within 4 months (blister) or 4 months (bottle, once opened). Do not use after the expiry date.
Proper storage of dabigatran is particularly important because the capsules are moisture-sensitive. Exposure to moisture can affect the drug’s stability and effectiveness. Follow these guidelines carefully:
- Original packaging: Always keep dabigatran capsules in the original blister packaging or bottle. Do not remove capsules from blisters until immediately before taking them.
- Moisture protection: Do not transfer capsules to pill boxes, pill organisers, or other containers. This is a critical difference from many other medications – dabigatran capsules must remain in their moisture-protective packaging until the moment of ingestion.
- Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not freeze.
- Blister packaging: Once an individual blister strip is opened, the capsules should be used within 4 months.
- Bottle packaging: Once the bottle is opened, the capsules must be used within 4 months. Keep the bottle tightly closed to protect from moisture. The desiccant capsule inside the bottle should not be removed.
- Coated granules (paediatric formulation): The aluminium pouch containing the dose sachets must not be opened before first use. Once opened, the product must be used within 6 months. Individual dose sachets cannot be saved once opened and must be used immediately.
- Children: Keep all medicines out of the sight and reach of children.
- Expiry: Do not use dabigatran after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not throw away medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need.
What Does Dabigatran Contain?
Quick Answer: Each dabigatran hard capsule contains dabigatran etexilate (as mesilate) in strengths of 75 mg, 110 mg, or 150 mg. The capsules contain a tartaric acid core to enhance absorption. Coated granules are available in strengths of 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, and 150 mg for paediatric use.
Understanding the composition of your medication can help identify potential allergens or excipients that may cause sensitivity. The formulation of dabigatran is specifically designed to optimise absorption and stability.
Active Ingredient
- Dabigatran etexilate 75 mg: Each hard capsule contains 75 mg dabigatran etexilate (as mesilate).
- Dabigatran etexilate 110 mg: Each hard capsule contains 110 mg dabigatran etexilate (as mesilate).
- Dabigatran etexilate 150 mg: Each hard capsule contains 150 mg dabigatran etexilate (as mesilate).
Excipients (Inactive Ingredients)
The following excipients are typically present in dabigatran hard capsules (based on the Pradaxa formulation):
- Capsule core pellets: Tartaric acid (creates a low-pH microenvironment for optimal absorption), acacia (gum arabic), hypromellose, dimethicone 350, talc, hydroxypropylcellulose.
- Capsule shell: Carrageenan, potassium chloride, titanium dioxide (E171), hypromellose, purified water, and colourants (indigo carmine [E132] and/or iron oxide yellow [E172] depending on strength).
- Printing ink: Shellac, iron oxide black (E172), potassium hydroxide.
Coated Granules (Paediatric Formulation)
The coated granule formulation for paediatric use contains the same active ingredient (dabigatran etexilate as mesilate) in strengths of 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, and 150 mg per dose sachet. Excipients include tartaric acid, acacia, hypromellose, dimethicone 350, talc, and hydroxypropylcellulose. The granules appear yellowish and should be mixed with apple juice or certain soft foods (mashed carrots, applesauce, or mashed banana) – not milk or dairy-containing foods.
The tartaric acid core of dabigatran capsules creates a localised acidic microenvironment that is essential for optimal drug absorption (bioavailability is only approximately 6.5% without this mechanism). However, this acidic component is thought to contribute to the higher incidence of dyspepsia and gastro-oesophageal reflux seen with dabigatran compared to other DOACs. Taking dabigatran with food or plenty of water may help mitigate these symptoms.
Frequently Asked Questions About Dabigatran
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (RE-ALIGN). N Engl J Med. 2013;369(13):1206–1214. doi:10.1056/NEJMoa1300615
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
- European Society of Cardiology. 2024 ESC/EACTS Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
- European Medicines Agency. Pradaxa (dabigatran etexilate) – Summary of Product Characteristics. EMA, 2024. EMA – Pradaxa
- U.S. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) – Prescribing Information. FDA, 2024. FDA – Pradaxa
- British National Formulary. Dabigatran etexilate. BNF, 2025. BNF – Dabigatran etexilate
- Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. N Engl J Med. 2013;368(14):1272–1274. doi:10.1056/NEJMp1302834
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement (RE-NOVATE II). Thromb Haemost. 2011;105(4):721–729.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in clinical pharmacology, haematology, and internal medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and anticoagulation therapy with extensive experience in evidence-based medical communication.
iMedic Medical Review Board – independent panel of medical experts who verify all content against current international guidelines (ESC, AHA/ACC, EMA, FDA, BNF, WHO).
All iMedic content follows the GRADE evidence framework and is based on Level 1A evidence (systematic reviews of randomised controlled trials) where available. We have no commercial funding or pharmaceutical sponsorship. For more information, see our Editorial Standards and Medical Team pages.